Status:
COMPLETED
Molar Potency Study of HM12470 in Healthy Subjects
Lead Sponsor:
Hanmi Pharmaceutical Company Limited
Conditions:
Healthy Subjects
Eligibility:
All Genders
18-60 years
Phase:
PHASE1
Brief Summary
This is a phase 1 study to assess and compare molar potency of HM12470 and regular human insulin in healthy subjects.
Eligibility Criteria
Inclusion
- Females must be non-pregnant and non-lactating
- Males must be surgically sterile or using an acceptable contraceptive method
Exclusion
- Participation in an investigational study within 30 days prior to dosing
- Use of new prescription and non-prescription drugs within 3 weeks preceding the first dosing
Key Trial Info
Start Date :
March 30 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 17 2017
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT03330327
Start Date
March 30 2015
End Date
August 17 2017
Last Update
November 6 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hanmi Investigative Site
Chula Vista, California, United States, 91911